Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Next deadline: Jan 7, 2024 (Letter of inquiry)

Later deadlines: Feb 7, 2024 (Full proposal)

Grant amount: Unspecified amount

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: All applications are due by 5:00 PM local time of applicant organization.

This Notice of Funding Opportunity (NOFO) aims to provide a proof-of-principle for a novel strategy for Alzheimer Disease and Alzheimer Related Dementias (AD/ADRD) immunotherapies. Specifically, the goal is to examine if a novel immunotherapeutic approach in cancer immunotherapy with Chimeric Antigen Receptor (CAR) immune cellscould be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.